Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clx-0921. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 9/20 | 1.00 |
| ▸ | MPC2 | O95563 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clx-0921 SCHEMBL3794540 | 1.00 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Clx-0921 SCHEMBL3798951 | 1.00 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6827386 | 0.93 | PPARG (0.88) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL12631345 | 0.93 | PPARG (0.86) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4434728 | 0.91 | PPARG (0.84) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4434725 | 0.91 | PPARG (0.84) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL3792635 | 0.91 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL3792638 | 0.91 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL3798936 | 0.91 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL3798938 | 0.91 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | claimed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | claimed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | claimed |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | claimed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220251153-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | UGH PHARMA, INC. (PA) | 2022-08-11 | — | — | US | claimed |
| EP-4021480-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | The George Washington University (US) | 2022-07-06 | — | — | EP | claimed |
| US-7718682-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1007039-B1 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | CALYX THERAPEUTICS INC (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1360178-A2 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | Calyx Therapeutics, Inc. (US) | 2003-11-12 | — | — | EP | claimed |
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | SEED, BRIAN | 2003-09-25 | — | — | US | claimed |
| US-20020032225-A1 | Novel heterocyclic analogs of diphenylethylene compounds | SEED, BRIAN | 2002-03-14 | — | — | US | claimed |
| US-20020025975-A1 | Novel Heterocyclic analogs of diphenylethylene compounds | CALYX THERAPEUTICS, INC. | 2002-02-28 | — | — | US | claimed |
| WO-2001095859-A2 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | CALYX THERAPEUTICS, INC. (US) | 2001-12-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885MPC2 1391/4885CYP2C8 2348/4885 |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | COL2A1, ALPI, COL14A1 | PPARG 1231/4885MPC2 1487/4885CYP2C8 4110/4885 |
| US-20020025975-A1 | Novel Heterocyclic analogs of diphenylethylene compounds | FFAR2, GPR119, FFAR4 | PPARG 25/4885MPC2 126/4885CYP2C8 2373/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | PPARG 1231/4885MPC2 1487/4885CYP2C8 4110/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885MPC2 1391/4885CYP2C8 2348/4885 |
| US-20020032225-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, GPR119, FFAR4 | PPARG 25/4885MPC2 154/4885CYP2C8 2246/4885 |
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | PPARG 10/4885MPC2 753/4885CYP2C8 1831/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 467/4885MPC2 1400/4885CYP2C8 1547/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885MPC2 1391/4885CYP2C8 2348/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885MPC2 1391/4885CYP2C8 2348/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885MPC2 1391/4885CYP2C8 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.